Research programme: antifibrotics - ProQR Therapeutics/Galapagos

Drug Profile

Research programme: antifibrotics - ProQR Therapeutics/Galapagos

Latest Information Update: 15 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galapagos NV; ProQR Therapeutics
  • Class Antifibrotics; Oligonucleotides
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Fibrosis

Most Recent Events

  • 08 Jan 2018 ProQR and Galapagos enters into a collaboration for development of oligonucleotides for Fibrosis
  • 08 Jan 2018 Early research in Fibrosis in Belgium (unspecified route)
  • 08 Jan 2018 Early research in Fibrosis in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top